In keeping with these results, GHRH antagonists of JMR and MZ classes in combination with cytotoxic agents, including cisplatin and taxans, have been reported to inhibit the in vitro and in vivo growth of different experimental cancers, such as breast, lung and colon cancers [37,38,39,40]. This evidence concerns the gene GHRH and cancer.